Background: In observational studies, high levels of gamma-glutamyltransferase (GGT) have been associated with a higher risk of type 2 diabetes mellitus (T2D). We aimed to assess whether this association is causal, using Mendelian randomization. Methods: A Mendelian randomization study was conducted using publicly available data from a genome-wide association study (GWAS) on T2D (12 171 cases of T2D and 56 862 controls), and additionally from GWAS on glycaemic traits ( N = 46 186) and HbA1c ( N = 46 368) in nondiabetic participants. Independent genetic variants (26 in total), identified in the largest GGT GWAS comprising studies of European ancestry, were used as genetic instruments. Inverse-variance weighted and MR-Egger regression analyses were used to estimate the effect of the combined genetic instrumental variables on T2D and glycaemic traits and HbA1c. Results: F-statistics of the 26 genetic instrumental variables, as a measure of instrumental strength, ranged from 23.4 ( ATP8B1 ) to 258.3 ( GGT1 ). Using inverse-variance analyses, we found no evidence of an association between the combined genetic instrumental variables for GGT and the risk of T2D, or glucose-, insulin- or HbA1c-levels. More specifically, a 10% higher genetically determined GGT was not associated with a higher risk of T2D (odds ratio: 0.99; 95% confidence interval: 0.95; 1.02). Results were similar for MR-Egger regression analyses, which did not show evidence for directional pleiotropy. Conclusion: The previously observed association between high levels of serum GGT and T2D in observational studies might not be causal. Likely, results from the observational studies can be explained by reverse causality and/or residual confounding.
Background: In observational studies, high levels of gamma-glutamyltransferase (GGT) have been associated with a higher risk of type 2 diabetes mellitus (T2D). We aimed to assess whether this association is causal, using Mendelian randomization. Methods: A Mendelian randomization study was conducted using publicly available data from a genome-wide association study (GWAS) on T2D (12 171 cases of T2D and 56 862 controls), and additionally from GWAS on glycaemic traits ( N = 46 186) and HbA1c ( N = 46 368) in nondiabetic participants. Independent genetic variants (26 in total), identified in the largest GGT GWAS comprising studies of European ancestry, were used as genetic instruments. Inverse-variance weighted and MR-Egger regression analyses were used to estimate the effect of the combined genetic instrumental variables on T2D and glycaemic traits and HbA1c. Results: F-statistics of the 26 genetic instrumental variables, as a measure of instrumental strength, ranged from 23.4 ( ATP8B1 ) to 258.3 ( GGT1 ). Using inverse-variance analyses, we found no evidence of an association between the combined genetic instrumental variables for GGT and the risk of T2D, or glucose-, insulin- or HbA1c-levels. More specifically, a 10% higher genetically determined GGT was not associated with a higher risk of T2D (odds ratio: 0.99; 95% confidence interval: 0.95; 1.02). Results were similar for MR-Egger regression analyses, which did not show evidence for directional pleiotropy. Conclusion: The previously observed association between high levels of serum GGT and T2D in observational studies might not be causal. Likely, results from the observational studies can be explained by reverse causality and/or residual confounding.
Authors: N Maneka G De Silva; Maria Carolina Borges; Aroon D Hingorani; Jorgen Engmann; Tina Shah; Xiaoshuai Zhang; Jian'an Luan; Claudia Langenberg; Andrew Wong; Diana Kuh; John C Chambers; Weihua Zhang; Marjo-Ritta Jarvelin; Sylvain Sebert; Juha Auvinen; Tom R Gaunt; Deborah A Lawlor Journal: Diabetes Date: 2019-05-14 Impact factor: 9.461
Authors: Raymond Noordam; Debbie Vermond; Hermijntje Drenth; Carolien A Wijman; Abimbola A Akintola; Sabrina van der Kroef; Steffy W M Jansen; Neline C Huurman; Bianca A M Schutte; Marian Beekman; P Eline Slagboom; Simon P Mooijaart; Diana van Heemst Journal: Front Endocrinol (Lausanne) Date: 2017-09-13 Impact factor: 5.555
Authors: Senthil K Vasan; Raymond Noordam; Mahasampath S Gowri; Matthew J Neville; Fredrik Karpe; Constantinos Christodoulides Journal: Diabetologia Date: 2019-07-15 Impact factor: 10.122
Authors: Inge Verkouter; Renée de Mutsert; Roelof A J Smit; Stella Trompet; Frits R Rosendaal; Diana van Heemst; Ko Willems van Dijk; Raymond Noordam Journal: Int J Epidemiol Date: 2020-08-01 Impact factor: 7.196
Authors: Raymond Noordam; Kristi Läll; Roelof A J Smit; Triin Laisk; Andres Metspalu; Tõnu Esko; Lili Milani; Ruth J F Loos; Reedik Mägi; Ko Willems van Dijk; Diana van Heemst Journal: Diabetes Date: 2021-05-10 Impact factor: 9.337